Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
11C-ORM-13070
- Development stage
- Phase 1
- Lead developer
- Orion
- Modality
- Alpha Emitters → Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Beta Emitters → Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous
01
Overview
**11C-ORM-13070** is a radiolabeled small molecule used as a positron emission tomography (PET) tracer for imaging the alpha2C-adrenoceptor (α2C-adrenoceptor, α2C-AR) in the brain. It acts as a selective antagonist of the α2C-adrenoceptor and is primarily utilized in research settings to study receptor distribution, occupancy, and engagement by candidate drugs targeting neuropsychiatric disorders such as depression, schizophrenia, and Alzheimer's disease. The compound was initially developed by Orion Oyj. Its mechanism of action involves binding selectively to the α2C-adrenoceptor subtype with high specificity and reversible kinetics suitable for PET imaging[1][2][4][7].
- Other names
- y61s1ufn4yy-61s1ufn4yy 61s1ufn4y1-(1-(2,3-dihydrobenzo(1,4)dioxin-2-yl)methyl)-4-(3-methoxymethylpyridin-2-yl)piperazine
02
Targets
ADRA2C (α2C)
Beyond the preview
Go deeper on 11C-ORM-13070.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on 11C-ORM-13070.